Stock Price & Analysis

Based on the recent data and market analysis, here is a concise assessment of ALNY stock:

Technical Analysis: The stock is currently showing bearish momentum with RSI at 39.26 indicating a neutral-to-bearish sentiment. The stock is trading below its key moving averages (SMA 5: 251.71, SMA 20: 268.29), suggesting downward pressure.

Recent Performance & News:

• Q4 2024 earnings released on February 13 showed strong performance with EPS of $0.06, significantly beating analysts' expectations of -$0.60
• Revenue reached $593.2 million, exceeding the expected $584 million
• The company's ATTR amyloidosis franchise (Onpattro and Amvuttra) generated $343 million in combined quarterly revenues, showing 35% YoY growth

Forward Outlook:

• Management has provided 2025 guidance for combined net product revenue of $2.05-2.25 billion
• The company anticipates achieving non-GAAP operating income profitability in 2025
• A Research and Development Day is scheduled for February 25 (tomorrow) which could impact stock movement

Recommendation: SELL

• Current technical indicators show weakness with price below key moving averages
• The stock is trading near support levels around $249.83 (Fibonacci S1)
• Despite strong fundamentals and positive earnings, market sentiment remains cautious
• Consider waiting for the R&D Day announcements tomorrow before making new positions

Based on recent data and market analysis, ALNY stock is projected to reach $320-340 by end of 2025, driven by strong Q4 2024 performance and potential approval of Amvuttra for ATTR-CM indication. The company's successful execution of P5x25 strategy targeting 500,000 patients worldwide and expanding pipeline of 25+ clinical programs supports this bullish outlook. Technical indicators showing current RSI at 39.26 and price near support levels around $250 suggest the stock is oversold and poised for upward movement.

The S1 support level for ALNY Stock is $238.97 ,The R1 resistant level for ALNY Stock is $260.64.

As of the end of day on 2025-03-03, the price of ALNY Stock was $243.52.

The target price for ALNY Stock according to analyst rating is 329.87, with the highest price target at 500.00 and the lowest at 284.00. Analysts have a Strong Buy rating on ALNY Stock overall.

The market cap of ALNY is $31.9B.

Based on the financial data and recent developments, ALNY appears to be reasonably valued at current levels. The company's revenue growth has been impressive with an 76% YoY increase to $1.83B in 2023, while significantly reducing its net loss from -$1.13B to -$440M. The PS ratio has improved substantially from 27.88x to 13.08x, indicating better operational efficiency. Technical indicators show the stock is currently oversold with RSI at 39.26 and trading below its 20-day SMA of $268.29, suggesting a potential bounce. The company expects to achieve non-GAAP profitability in 2025 with projected product revenues of $2.05-2.25B.

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Based on the available data and market analysis, here is the price prediction for ALNY stock by 2030:

ALNY stock is projected to reach $450-500 by 2030, driven by the company's strong RNAi therapeutics pipeline and expanding global market presence. The company's P5x25 strategic plan aims to treat over 500,000 patients worldwide by end of 2025, which should significantly boost revenues. Recent Q4 2024 earnings beat with $593.2 million revenue and successful commercialization of key products Onpattro and Amvuttra demonstrate solid execution.

The stock's current technical indicators and recent insider selling patterns suggest near-term consolidation, but long-term growth trajectory remains intact with Needham maintaining $320 price target.

ALNY has a total of 2100 employees.